Abstract
Objective To determine whether lipid microspheres containing prostaglandin E 1 (lipo-PGE 1 ) improve pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension (PAH) Methods Forty-nine patients with PAH (8 patients with primary pulmonary hypertension, 21 patients with collagen vascular disease, 20 patients with congenital systemic-to-pulmonary shunts) were randomly classified into a conventional therapy group (n = 22) or a group receiving lipo-PGE 1 plus conventional drugs (lipo-PGE 1 group; n = 27). Echocardiographic pulmonary parameters, New York Heart Association (NYHA) functional class, and Bruce treadmill test results for exercise capacity were recorded before and after treatment Results After 2 weeks of treatment with lipo-PGE 1 (10 μg bid for 14 days), there were significant improvements in the values (± SD) for systolic pulmonary arterial pressure (SPAP) [76.9 ± 27.9 mm Hg vs 66.5 ± 22.8 mm Hg, p −5 vs 20.2 ± 10.7 dyne·s·cm −5 , p 1 group achieved significant reduction of SPAP (10.4 ± 10.3 mm Hg vs 2.2 ± 5.6 mm Hg, p = 0.002) and a significant elevation of exercise capacity (1.5 ± 0.9 MET vs 0.6 ± 1.1 MET, p = 0.018) Conclusion Lipo-PGE 1 can decrease pulmonary artery pressure and increase exercise capacity in patients with PAH
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
